Haemonetics Corporation (NYSE:HAE) Q4 2026 Earnings Call Transcript
Operator: Hello, and welcome to the Q4 2026 Haemonetics Corporation's earnings conference call. [Operator Instructions] Please be advised that today's conference is being recorded.
Haemonetics Corp (HAE)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 8,013,000 | $7,666,838 | 0.03% | ||
| 2. | Royce & Associates Chuck Royce | 71,475 | $4,028,331 | 0.04% | |
| 3. | Walleye Capital Will England | 66,359 | $3,739,993 | +11% | 0.02% |
| 4. | Skylands Capital Charles Paquelet | 65,825 | $3,709,897 | +81% | 0.49% |
| 5. | Levin Easterly Partners John Murphy | 31,122 | $1,724,303 | +5% | 0.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $70.56 | 1,400 | $98,784.00 | 24,757 | 2025-11-10 | Filing | |
| $80.93 | 4,000 | $323,720.00 | 12,048 | 2020-08-11 | Filing | |
| $35.00 | 60,000 | $2,099,754.00 | 105,867 | 2016-08-04 | Filing | |
| $32.73 | 412 | $13,482.70 | 31,522 | 2013-04-30 | Filing | |
| $32.73 | 615 | $20,125.88 | 17,279 | 2013-04-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $91.15 | 4,312 | $393,038.80 | 18,196 | 2024-07-26 | Filing | |
| $90.00 | 79 | $7,110.00 | 21,331 | 2024-07-12 | Filing | |
| $90.00 | 2,136 | $192,240.00 | 21,410 | 2024-07-11 | Filing | |
| $88.57 | 4,094 | $362,605.58 | 31,257 | 2024-05-29 | Filing | |
| $87.86 | 8,896 | $781,602.56 | 35,351 | 2024-05-29 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,559,316 | $144,243,050 | 0.01% | |
| 2. | 2,090,389 | $117,814,324 | 0% | |
| 3. | 1,327,989 | $74,845,460 | 0.85% | |
| 4. | 1,326,057 | $74,730,645 | 0.02% | |
| 5. | 890,224 | $50,066,198 | 0.08% |
News See All
Riverwater Sustainable Value Strategy Awaits Haemonetics Corporation’s (HAE) Market Validation
Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q1 2026 investor letter. A copy of the letter can be downloaded here.
Mizuho Adjusts Haemonetics Corporation (HAE) Estimates in Sector-Wide Review
TheFly reported on April 13 that Mizuho analyst Anthony Petrone reduced the price target for HAE to $70 from $80 while maintaining an Outperform rating.
10 Best Healthcare Stocks to Buy and Hold for 3 Years
The first quarter of this year has seen a great deal of volatility in the equity markets. The S&P 500 fell into correction territory before rising again after first soaring to all-time highs.
Haemonetics Corporation (HAE) Q3 Performance Prompts Baird Model Update, Price Target Falls to $81
TheFly reported on February 6 that Baird lowered its price target for HAE to $81 from $99 while maintaining an Outperform rating.
Strong Competitive Position Drove Haemonetics Corporation’s (HAE) Earnings Growth
Aristotle Capital Boston, LLC, an investment advisor, released its fourth-quarter investor letter for “Small Cap Equity Fund”. A copy of the letter can be downloaded here. U.S.
15 Innovative Healthcare Stocks to Buy According to Analysts
Over the last two years, artificial intelligence has propelled global financial markets into a boom, with stocks reaching all-time highs.
Haemonetics Corporation (NYSE:HAE) Q3 2026 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Third Quarter 2026 Haemonetics Corporation Earnings Conference Call. At this time, participants are in a listen-only mode.
Haemonetics (HAE) Sparks Confidence Following Vivasure Acquisition
On January 12, Michael Petusky from Barrington maintained his Outperform rating on Haemonetics Corporation (NYSE:HAE).
12 Best Medical Devices Stocks to Invest In According to Hedge Funds
It is challenging to identify segments within the markets that appear to be defensive plays, yet offer innovation potential.